CTLA4 and melanoma: In this study, we combined functional analysis of short-term melanoma cell models with high dimensional flow cytometric profiling of matched tumor samples from melanoma patients progressing on PD1 inhibitor monotherapy or in combination with the CTLA4 inhibitor, ipilimumab.